Literature DB >> 23651110

The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area.

Eun Sun Jang1, Sook-Hyang Jeong, Sang Hyub Lee, Sung Ho Hwang, So Yeon Ahn, Jaebong Lee, Young Soo Park, Jin Hyoek Hwang, Jin-Wook Kim, Nayoung Kim, Dong Ho Lee, Hyun Young Kim.   

Abstract

BACKGROUND & AIMS: Coffee consumption is inversely related to the risk of cirrhosis or hepatocellular carcinoma (HCC). However, the protective effect of coffee drinking against the risk of HCC was not established in HBV-prevalent region. To elucidate the relationship between lifetime coffee consumption and the risk of HCC development under the consideration of replication status of HBV.
METHODS: A hospital-based case-control study was performed in 1364 subjects. A total of 258 HCC patients, 480 health-check examinees (control 1, HCE) and 626 patients with chronic liver disease other than HCC (control 2, CLD) were interviewed on smoking, alcohol and coffee drinking using a standardized questionnaire. HBV e-antigen (HBeAg) status and serum HBV DNA levels were measured in patients infected with HBV.
RESULTS: After adjustment for age, gender, obesity, DM, presence of hepatitis virus (except for HCE) and lifetime alcohol drinking/smoking, a high lifetime coffee consumption (≥20 000 cups) was an independent protective factor against HCC, in each analyses using healthy and risky control groups respectively (HCE group, OR 0.56, 95% CI 0.33-0.95; CLD group, OR 0.55, 95% CI 0.36-0.85). However, the high coffee consumption did not affect the HCC risk in patients with HBV (OR 0.64, 95% CI 0.36-1.14) after adjustment for HBeAg status, serum HBV DNA level and antiviral therapy.
CONCLUSIONS: A high lifetime coffee consumption was negatively associated with a HCC development. However, this difference of coffee exposure with the HCC group was reduced in chronic hepatitis B patients by the dominant role of viral replication.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alcohol; chronic hepatitis B; coffee; hepatitis B e-antigen; hepatocellular carcinoma; smoking

Mesh:

Substances:

Year:  2013        PMID: 23651110     DOI: 10.1111/liv.12186

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

Review 1.  Coffee Drinking and Reduced Risk of Liver Cancer: Update on Epidemiological Findings and Potential Mechanisms.

Authors:  Manami Inoue; Shoichiro Tsugane
Journal:  Curr Nutr Rep       Date:  2019-09

2.  Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.

Authors:  Yan Wu; Yu Gan; Fumin Gao; Zhimei Zhao; Yan Jin; Yu Zhu; Zhihan Sun; Hao Wu; Taoyang Chen; Jinbing Wang; Yan Sun; Chunsun Fan; Yongbing Xiang; Gengsun Qian; John D Groopman; Jianren Gu; Hong Tu
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

3.  Raf/ERK/Nrf2 signaling pathway and MMP-7 expression involvement in the trigonelline-mediated inhibition of hepatocarcinoma cell migration.

Authors:  Jung Chun Liao; Kun Tsung Lee; Bang Jau You; Chia Lin Lee; Wen Te Chang; Yang Chang Wu; Hong-Zin Lee
Journal:  Food Nutr Res       Date:  2015-12-22       Impact factor: 3.894

4.  Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B.

Authors:  Alexander Hodge; Sarah Lim; Evan Goh; Ophelia Wong; Philip Marsh; Virginia Knight; William Sievert; Barbora de Courten
Journal:  Nutrients       Date:  2017-01-10       Impact factor: 5.717

5.  Increased Coffee Intake Reduces Circulating HBV DNA and HBsAg Levels in HBeAg-Negative Infection: A Cohort Study.

Authors:  Jack Bee Chook; Yun Fong Ngeow; Kok Keng Tee; Jamie Wan Ting Lee; Rosmawati Mohamed
Journal:  Viruses       Date:  2019-09-01       Impact factor: 5.048

6.  Coffee consumption and NAFLD: a community based study on 1223 subjects.

Authors:  Tilmann Graeter; Pia C Niedermayer; Richard A Mason; Suemeyra Oeztuerk; Mark M Haenle; Wolfgang Koenig; Bernhard Otto Boehm; Wolfgang Kratzer
Journal:  BMC Res Notes       Date:  2015-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.